BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31008565)

  • 1. Dendrimer mediated targeting of siRNA against polo-like kinase for the treatment of triple negative breast cancer.
    Jain A; Mahira S; Majoral JP; Bryszewska M; Khan W; Ionov M
    J Biomed Mater Res A; 2019 Sep; 107(9):1933-1944. PubMed ID: 31008565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of cationic liposome and PAMAM dendrimer for delivery of anti-Plk1 siRNA in breast cancer treatment.
    Bulbake U; Kommineni N; Ionov M; Bryszewska M; Khan W
    Pharm Dev Technol; 2020 Jan; 25(1):9-19. PubMed ID: 30633621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion.
    Li J; Liu J; Li S; Hao Y; Chen L; Zhang X
    Oncotarget; 2016 Mar; 7(12):13782-96. PubMed ID: 26883109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Ha GH; Kim DY; Breuer EK; Kim CK
    Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
    Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of PLK1 inhibition in triple-negative breast cancer.
    Ueda A; Oikawa K; Fujita K; Ishikawa A; Sato E; Ishikawa T; Kuroda M; Kanekura K
    Lab Invest; 2019 Sep; 99(9):1275-1286. PubMed ID: 30996295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Allosteric Inhibitor Targets PLK1 in Triple Negative Breast Cancer Cells.
    Patel JR; Thangavelu P; Terrell RM; Israel B; Sarkar AB; Davidson AM; Zhang K; Khupse R; Tilghman SL
    Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro and In Vivo Co-delivery of siRNA and Doxorubicin by Folate-PEG-Appended Dendrimer/Glucuronylglucosyl-β-Cyclodextrin Conjugate.
    Mohammed AFA; Higashi T; Motoyama K; Ohyama A; Onodera R; Khaled KA; Sarhan HA; Hussein AK; Arima H
    AAPS J; 2019 Apr; 21(4):54. PubMed ID: 30993472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
    Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
    Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
    Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
    Giordano A; Liu Y; Armeson K; Park Y; Ridinger M; Erlander M; Reuben J; Britten C; Kappler C; Yeh E; Ethier S
    PLoS One; 2019; 14(11):e0224420. PubMed ID: 31751384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorus dendrimers as carriers of siRNA--characterisation of dendriplexes.
    Ferenc M; Pedziwiatr-Werbicka E; Nowak KE; Klajnert B; Majoral JP; Bryszewska M
    Molecules; 2013 Apr; 18(4):4451-66. PubMed ID: 23591925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
    Medina-Aguilar R; Marchat LA; Arechaga Ocampo E; Gariglio P; García Mena J; Villegas Sepúlveda N; Martínez Castillo M; López-Camarillo C
    Oncol Rep; 2016 Jun; 35(6):3696-704. PubMed ID: 27109433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma.
    Shi H; Sun S; Xu H; Zhao Z; Han Z; Jia J; Wu D; Lu J; Liu H; Yu R
    Int J Nanomedicine; 2020; 15():3347-3362. PubMed ID: 32494134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic opportunities for PLK1 inhibitors: Spotlight on BRCA1-deficiency and triple negative breast cancers.
    García IA; Garro C; Fernandez E; Soria G
    Mutat Res; 2020; 821():111693. PubMed ID: 32172132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
    Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
    Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.
    Dou S; Yang XZ; Xiong MH; Sun CY; Yao YD; Zhu YH; Wang J
    Adv Healthc Mater; 2014 Nov; 3(11):1792-803. PubMed ID: 24947820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer.
    Mahajan UM; Teller S; Sendler M; Palankar R; van den Brandt C; Schwaiger T; Kühn JP; Ribback S; Glöckl G; Evert M; Weitschies W; Hosten N; Dombrowski F; Delcea M; Weiss FU; Lerch MM; Mayerle J
    Gut; 2016 Nov; 65(11):1838-1849. PubMed ID: 27196585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.